BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Di Paolo A, Luci G. Personalized Medicine of Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacogenetics, Therapeutic Drug Monitoring, and Beyond. Front Pharmacol 2020;11:610806. [PMID: 33628180 DOI: 10.3389/fphar.2020.610806] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Papamichael K, Cheifetz AS. Optimizing therapeutic drug monitoring in inflammatory bowel disease: a focus on therapeutic monoclonal antibodies. Expert Opinion on Drug Metabolism & Toxicology. [DOI: 10.1080/17425255.2021.2027367] [Reference Citation Analysis]
2 Mingas PD, Zdovc J, Grabnar I, Vovk T. The Evolving Role of Microsampling in Therapeutic Drug Monitoring of Monoclonal Antibodies in Inflammatory Diseases. Molecules 2021;26:1787. [PMID: 33810104 DOI: 10.3390/molecules26061787] [Reference Citation Analysis]
3 Scalavino V, Piccinno E, Bianco G, Schena N, Armentano R, Giannelli G, Serino G. The Increase of miR-195-5p Reduces Intestinal Permeability in Ulcerative Colitis, Modulating Tight Junctions' Expression. Int J Mol Sci 2022;23:5840. [PMID: 35628650 DOI: 10.3390/ijms23105840] [Reference Citation Analysis]
4 Luci G, Cucchiara F, Ciofi L, Mattioli F, Lastella M, Danesi R, Di Paolo A. Determination of Mitotane (DDD) and Principal Metabolite by a Simple HPLC-UV Method and Its Validation in Human Plasma Samples. Separations 2021;8:63. [DOI: 10.3390/separations8050063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Chen F, Liu Q, Xiong Y, Xu L. Current Strategies and Potential Prospects of Nanomedicine-Mediated Therapy in Inflammatory Bowel Disease. Int J Nanomedicine 2021;16:4225-37. [PMID: 34188471 DOI: 10.2147/IJN.S310952] [Reference Citation Analysis]